Dataset

DZNE-2025-01385

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Dataset: CSF proteomics of aducanumab treated APP-SAA triple knock-in mice (Project PXD061932)

Müller, S. A.DZNE* ; Lichtenthaler, S.DZNE*

2025
PRoteomics IDEntifications Database

Abstract: Anti-amyloid β-peptide (Aβ) immunotherapy was developed as treatment for Alzheimer’s disease to reduce and prevent amyloid plaque pathology and its downstream consequences. Efficient amyloid plaque clearance has been proven in clinical trials with Aducanumab, Lecanemab and Donanemab. At least two of these antibodies slow memory decline to some extent and have beneficial effects on daily living act...

---

Contributing Institute(s):

1. Neuroproteomics (AG Lichtenthaler)

Research Program(s):

1. 352 - Disease Mechanisms (POF4-352) (POF4-352)

Appears in the scientific report 2025

---

---

Linked articles:

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article de Weerd, L. (First author)DZNE* ; Hummel, S.Extern* ; Müller, S. A.DZNE* ; Paris, I. ; Sandmann, T. ; Eichholtz, M. ; Gröger, R. ; Englert, A. L. ; Wagner, S. ; Ha, C. ; Davis, S. S. ; Warkins, V. ; Xia, D. ; Nuscher, B. ; Berghofer, A.DZNE* ; Reich, M.DZNE* ; Feiten, A. F.Extern* ; Schlepckow, K.DZNE* ; Willem, M. ; Lichtenthaler, S. F.DZNE* ; Lewcock, J. W. ; Monroe, K. M. ; Brendel, M.DZNE* ; Haass, C. (Last author)DZNE*
Early intervention anti-Aβ immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques.
Molecular neurodegeneration 20(1), 92 (2025) [10.1186/s13024-025-00878-1]2025   Files  Fulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS

---